paratek
pharmaceuticals
report
third
quarter
financial
results
november
boston
globe
newswire
paratek
pharmaceuticals
nasdaq
prtk
biopharmaceutical
company
focused
development
commercialization
novel
therapies
diseases
public
health
threats
civilian
government
military
use
today
announced
company
host
conference
call
live
audio
webcast
thursday
november
est
report
financial
results
quarter
ended
september
provide
corporate
update
audio
webcast
accessed
events
presentations
investor
relations
section
company
website
domestic
investors
wishing
participate
call
dial
international
investors
dial
conference
id
investors
also
access
call
http
paratek
pharmaceuticals
paratek
pharmaceuticals
biopharmaceutical
company
focused
development
commercialization
novel
therapies
diseases
public
health
threats
civilian
government
military
use
company
lead
commercial
product
omadacycline
oral
intravenous
antibiotic
available
treatment
adults
bacterial
pneumonia
acute
bacterial
skin
skin
structure
infections
paratek
collaboration
agreement
zai
lab
development
commercialization
omadacycline
greater
china
region
retains
remaining
global
rights
paratek
exclusively
licensed
rights
rights
greater
china
territory
sarecycline
oral
therapy
treatment
moderate
severe
acne
vulgaris
almirall
llc
almirall
paratek
retains
development
commercialization
rights
sarecycline
rest
world
paratek
awarded
contract
biomedical
advanced
research
development
authority
barda
support
development
nuzyra
treatment
pulmonary
anthrax
information
visit
follow
paratekpharma
twitter
nuzyra
omadacycline
novel
antibiotic
oral
intravenous
formulations
treatment
bacterial
pneumonia
cabp
acute
bacterial
skin
skin
structure
infections
absssi
modernized
tetracycline
nuzyra
specifically
designed
overcome
tetracycline
resistance
exhibits
activity
across
spectrum
bacteria
including
atypicals
strains
please
see
full
prescribing
information
nuzyra
forward
looking
statements
press
release
contains
statements
including
statements
related
overall
strategy
products
prospects
potential
statements
statements
historical
facts
included
press
release
statements
identified
words
advancing
expect
look
forward
anticipate
continue
words
terms
similar
meaning
statements
based
upon
current
expectations
involve
substantial
risks
uncertainties
may
actually
achieve
plans
carry
intentions
meet
expectations
projections
disclosed
statements
place
undue
reliance
statements
actual
results
timing
events
could
differ
materially
included
statements
result
risks
uncertainties
risk
factors
discussed
risk
factors
elsewhere
annual
report
form
year
ended
december
filings
securities
exchange
commission
expressly
disclaim
obligation
undertaking
update
revise
statements
contained
herein
